Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

The role of academic institutions in the development of drugs for rare and neglected diseases.

Coles LD, Cloyd JC.

Clin Pharmacol Ther. 2012 Aug;92(2):193-202. doi: 10.1038/clpt.2012.83. Review.

PMID:
22760003
2.

The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.

Macleod S, Lasko P, Mackenzie A.

J Popul Ther Clin Pharmacol. 2014;21(1):e47-55.

PMID:
24671865
3.

How academic labs can approach the drug discovery process as a way to synergize with big pharma.

Loregian A, Palù G.

Trends Microbiol. 2013 Jun;21(6):261-4. doi: 10.1016/j.tim.2013.03.006.

PMID:
23731493
4.

New models for pharmaceutical innovation in low-income countries.

Ardal C, Iversen JH, Myhr K.

Tidsskr Nor Laegeforen. 2011 Oct 18;131(20):2016-8. doi: 10.4045/tidsskr.11.0658. English, Norwegian. No abstract available.

5.

In silico repositioning of approved drugs for rare and neglected diseases.

Ekins S, Williams AJ, Krasowski MD, Freundlich JS.

Drug Discov Today. 2011 Apr;16(7-8):298-310. doi: 10.1016/j.drudis.2011.02.016. Review.

PMID:
21376136
6.

Expert Delphi survey on research and development into drugs for neglected diseases.

Fehr A, Thürmann P, Razum O.

BMC Health Serv Res. 2011 Nov 16;11:312. doi: 10.1186/1472-6963-11-312.

7.

Financing R&D for neglected diseases.

Herrling PL.

Nat Rev Drug Discov. 2009 Feb;8(2):91. doi: 10.1038/nrd2818. No abstract available.

PMID:
19189425
8.

NIH TRND program: successes in preclinical therapeutic development.

McKew JC, Pilon AM.

Trends Pharmacol Sci. 2013 Feb;34(2):87-9. doi: 10.1016/j.tips.2012.10.001. No abstract available.

9.
10.

Orphan drug development: an economically viable strategy for biopharma R&D.

Meekings KN, Williams CS, Arrowsmith JE.

Drug Discov Today. 2012 Jul;17(13-14):660-4. doi: 10.1016/j.drudis.2012.02.005.

PMID:
22366309
11.

Drug discovery: new models for industry-academic partnerships.

Tralau-Stewart CJ, Wyatt CA, Kleyn DE, Ayad A.

Drug Discov Today. 2009 Jan;14(1-2):95-101. doi: 10.1016/j.drudis.2008.10.003. Review.

PMID:
18992364
12.

First Universities Allied for Essential Medicines (UAEM) Neglected Diseases and Innovation Symposium.

Musselwhite LW, Maciag K, Lankowski A, Gretes MC, Wellems TE, Tavera G, Goulding RE, Guillen E.

Am J Trop Med Hyg. 2012 Jan;86(1):65-74. doi: 10.4269/ajtmh.2012.11-0608.

13.

Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges.

Ioset JR, Chang S.

Future Med Chem. 2011 Sep;3(11):1361-71. doi: 10.4155/fmc.11.102.

PMID:
21879842
14.

Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.

Gaspar R, Aksu B, Cuine A, Danhof M, Takac MJ, Linden HH, Link A, Muchitsch EM, Wilson CG, Ohrngren P, Dencker L.

Eur J Pharm Sci. 2012 Dec 18;47(5):979-87. doi: 10.1016/j.ejps.2012.09.020.

PMID:
23046836
15.

The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?

Wellman-Labadie O, Zhou Y.

Health Policy. 2010 May;95(2-3):216-28. doi: 10.1016/j.healthpol.2009.12.001.

PMID:
20036435
16.

A new era of hope for the world's most neglected diseases.

[No authors listed]

PLoS Med. 2005 Sep;2(9):e323. No abstract available.

17.

Matchmaking service links up researchers to wallflower drugs.

Schubert C.

Nat Med. 2010 Jan;16(1):7. doi: 10.1038/nm0110-7b. No abstract available.

PMID:
20057395
18.

Translation of rare disease research into orphan drug development: disease matters.

Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.

Drug Discov Today. 2009 Dec;14(23-24):1166-73. doi: 10.1016/j.drudis.2009.09.008. Review.

PMID:
19818412
19.

Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.

Valverde AM, Reed SD, Schulman KA.

Health Aff (Millwood). 2012 Nov;31(11):2528-35. doi: 10.1377/hlthaff.2012.0235. Review.

20.

Orphan drug legislation: lessons for neglected tropical diseases.

Villa S, Compagni A, Reich MR.

Int J Health Plann Manage. 2009 Jan-Mar;24(1):27-42. doi: 10.1002/hpm.930.

PMID:
18435430
Items per page

Supplemental Content

Support Center